Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2016
Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.
Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 63 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enhanced Recovery After Surgery (ERAS) Program Versus Conventional Perioperative Strategies in Patients Undergoing Gynecologic Oncologic Surgery: A Randomized Controlled Trial
Who cites it
63 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Guideline
- The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis.BMC women's health · 2024Pooled it
- Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023Pooled it
- Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.The Cochrane database of systematic reviews · 2022Pooled it
- Relationship between initiation time of adjuvant chemotherapy and survival in ovarian cancer patients: a dose-response meta-analysis of cohort studies.Scientific reports · 2017Pooled it
- Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis.American journal of therapeuticsPooled it
- Effect of intraperitoneal ropivacaine during and after cytoreductive surgery on time-interval to adjuvant chemotherapy in advanced ovarian cancer: a randomised, double-blind phase III trial.British journal of anaesthesia · 2025Trial
- Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Extrapancreatic extension exhibits tumor size-dependent prognostic impact in pancreatic cancer.Scientific reports · 2026Article
- Age Modifies the Prognostic Impact of Sex in Follicular Thyroid Carcinoma: A SEER Database Analysis.Annals of surgical oncology · 2026Article
- Predictors of postoperative morbidity and delayed initiation of adjuvant chemotherapy after cytoreductive surgery in advanced-stage epithelial ovarian cancer.World journal of surgical oncology · 2026Article
- Extrapancreatic extension modifies chemotherapy benefit in resected pancreatic ductal adenocarcinoma: a population-based cohort study.Scientific reports · 2026Article
- Diagnostic performance of artificial intelligence for detecting peritoneal and small bowel dissemination in epithelial ovarian cancer using preoperative contrast-enhanced CT imaging.Scientific reports · 2026Article
- Dose-response relationship between ascites volume and survival in high-grade serous ovarian cancer: a prospective cohort study.Gland surgery · 2026Article
- Higher lymph node burden predicts greater chemotherapy benefit in resected pancreatic ductal adenocarcinoma: evidence from 22,045 patients.Scientific reports · 2026Article
- Anastomotic leakage after rectosigmoid resection with primary anastomosis during cytoreductive surgery for advanced high-grade serous ovarian cancer: risk factors and oncologic outcomes.Journal of ovarian research · 2026Article
- Age-dependent effects of surgical approach in T3b differentiated thyroid carcinoma: a population-based analysis using machine learning.Endocrine-related cancer · 2025Article
- Earlier is not always better: Optimal time to initiate adjuvant chemotherapy after surgery for ovarian cancer.Archives of gynecology and obstetrics · 2025Article
- Optimal timing of primary debulking surgery in advanced ovarian cancer: insights from the TRUST trial.Journal of gynecologic oncology · 2025Article
- The Relation Between Post-Operative Surgical Site Infection and Time to Start Adjuvant Treatment in Ovarian and Uterine Cancers.Current oncology (Toronto, Ont.) · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTo determine whether time from surgery to initiation of chemotherapy impacts survival in advanced ovarian carcinoma. PATIENTS AND
methodsThis is a post-trial ad hoc analysis of Gynecologic Oncology Group protocol 218, a phase III randomized, double-blind, placebo-controlled trial designed to study the antiangiogenesis agent, bevacizumab, in primary and maintenance therapy for patients with newly diagnosed advanced ovarian carcinoma. Maximum attempt at debulking was an eligibility criterion. Stage III patients, not stage IV, were required to have gross macroscopic or palpable residual disease following surgery. The survival impact of time from surgery to initiation of chemotherapy was studied using Cox regression models and stratified by treatment arm, residual disease and other clinical and pathologic factors.
resultsOne thousand seven hundred eighteen assessable patients were randomized (stage III (n = 1237); stage IV (n = 477), including those with complete resection (stage IV only, n = 81), low-volume residual (≤1 cm, n = 701), and suboptimal (>1 cm, n = 932). On multivariate analysis, time to chemotherapy initiation was predictive of overall survival (P < 0.001), with the complete resection group (i.e. stage IV) encountering an increased risk of death when time to initiation of chemotherapy exceeded 25 days (95% confidence interval 16.6-49.9 days).
conclusionSurvival for women with advanced ovarian cancer may be adversely affected when initiation of chemotherapy occurs >25 days following surgery. Our analysis applies to stage IV only as women with stage III who underwent complete resection were not eligible for this trial. These results, however, are consistent with Gompertzian first-order kinetics where patients with microscopic residual are most vulnerable. CLINICAL TRIALS IDENTIFIER: NCT00262847.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.